Home › Crohn's Disease › Connecticut
Pag-aaral pangklinika para sa Crohn's Disease sa Connecticut
14 pag-aaral para sa Crohn's Disease ang naghahanap ng mga kalahok sa mga site sa Connecticut.
Mga Lungsod sa Connecticut
Opisyal na teksto ng pag-aaral (English)
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- Connecticut Clinical Research Institute ( Site 0297), Bristol
Nagre-recruitPhase 3
Lahat ng edad · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06651281A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Yale University School of Medicine-Digestive Disease ( Site 5019), New Haven
Nagre-recruitPhase 3
Edad 16 hanggang 80 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06430801Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Danbury Hospital, Western Connecticut Health Network /ID# 265556, Danbury
- Yale University School of Medicine /ID# 266786, New Haven
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Medical Research Center of Connecticut, Hamden
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07499232Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Smilow Cancer Center/Yale-New Haven Hospital, New Haven
- Yale University, New Haven
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT03816345An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Yale University Digestive Disease-Site Number: 8400108, New Haven
Nagre-recruitPhase 3
Edad 16 hanggang 80 · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07184931A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Connecticut Children's Medical Center, Hartford
Nagre-recruitPhase 3
Edad 2 hanggang 19 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT04844606A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Medical Research Center of Connecticut, LLC, Hamden
Nagre-recruitPhase 4
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06045754A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Connecticut Children's Medical Center, Hartford
Nagre-recruitPhase 3
Edad 2 hanggang 17 · Lahat ng kasarian · Na-update Ago 24, 2026 · NCT05509777Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- Yale University, New Haven
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 7, 2026 · NCT05230173Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- Yale University School of Medicine, New Haven
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 5, 2026 · NCT07237516Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD
- Connecticut Children's Medical Center, Hartford
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 10 hanggang 21 · Lahat ng kasarian · Na-update Hul 16, 2026 · NCT07224113Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- Connecticut Children's Medical Center - Hartford /ID# 262256, Hartford
Nagre-recruitPhase 3
Edad 2 hanggang 17 · Lahat ng kasarian · Na-update Hun 24, 2026 · NCT06332534Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Connecticut Children's Medical Center, Hartford
Nagre-recruitPhase 4
Edad 6 hanggang 17 · Lahat ng kasarian · Na-update May 27, 2026 · NCT05781152Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.